Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) · 2009
Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jena Anupam, Sachdeva Ravinder K, Sharma Aman, Wanchu Ajay
Аннотация
BACKGROUND: Few studies have addressed the issue of adverse drug reactions with non-protease inhibitor (PI)-based antiretroviral therapy (ART) in resource-constrained settings. We studied prospectively the incidence of adverse drug reactions with generic ART among our patients.
METHODOLOGY: A total of 100 HIV-infected individuals were recruited. Patients received nevirapine (NVP) or efavirenz (EFV) with lamivudine (3TC) and zidovudine (ZDV)/stavudine (d4T). They were followed for 6 months for evidence of adverse drug reactions.
RESULTS: The mean CD4 count was 114.09 +/- 60.07 cells/mm(3) (range, 12-232 cells/mm(3)). Transient gastrointestinal symptoms were most frequent. Fourteen individuals (12 receiving ZDV/d4T, 3TC, NVP and 2 receiving ZDV/d4T, 3TC, EFV) developed skin rash. Among patients receiving NVP, 25.7% developed grade 1 hepatotoxicity. Three patients had numbness in both lower limbs. Among those individuals who received EFV, 32.3% individuals had central nervous system (CNS) symptoms in the form of insomnia, vivid dreams, dizziness, and drowsiness.
CONCLUSION: As the developing world increasingly uses generic ART, the clinician must be constantly vigilant for treatment-related adverse events.
METHODOLOGY: A total of 100 HIV-infected individuals were recruited. Patients received nevirapine (NVP) or efavirenz (EFV) with lamivudine (3TC) and zidovudine (ZDV)/stavudine (d4T). They were followed for 6 months for evidence of adverse drug reactions.
RESULTS: The mean CD4 count was 114.09 +/- 60.07 cells/mm(3) (range, 12-232 cells/mm(3)). Transient gastrointestinal symptoms were most frequent. Fourteen individuals (12 receiving ZDV/d4T, 3TC, NVP and 2 receiving ZDV/d4T, 3TC, EFV) developed skin rash. Among patients receiving NVP, 25.7% developed grade 1 hepatotoxicity. Three patients had numbness in both lower limbs. Among those individuals who received EFV, 32.3% individuals had central nervous system (CNS) symptoms in the form of insomnia, vivid dreams, dizziness, and drowsiness.
CONCLUSION: As the developing world increasingly uses generic ART, the clinician must be constantly vigilant for treatment-related adverse events.
Предметные рубрики MeSH
Abdominal PainAdultAgedAlkynesAppetiteBenzoxazinesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCyclopropanesDizzinessDreamsDrug Therapy, CombinationExanthemaFemaleHIV InfectionsHumansHypesthesiaLamivudineMaleMiddle AgedNauseaNevirapineProspective StudiesReverse Transcriptase InhibitorsSleep Initiation and Maintenance DisordersSleep StagesStavudineVomitingZidovudine